Loading...
Market
What will be Seelos Therapeutics' stock price at the end of Q2 2025?
2
Resolution / Starting Odds
Above $10 • 25%
$5 - $10 • 25%
$1 - $5 • 25%
Below $1 • 25%
Stock price data from financial markets
Story
Seelos Therapeutics ($SEEL) Signs Agreement with USAMMDA to Evaluate SLS-002 for PTSD, Stock Surges 115.8%
Sep 24, 2024, 12:38 PM
Seelos Therapeutics ($SEEL) has announced the signing of a Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate its intranasal ketamine, SLS-002, for the treatment of PTSD. This agreement includes the inclusion of SLS-002 in the U.S. Department of Defense’s M-PACT trial, which will begin dosing in the fourth quarter of 2024. The Phase II trial will assess the safety, efficacy, and tolerability of SLS-002 in active-duty service members and veterans. Following this announcement, Seelos Therapeutics' stock surged by 115.8% in pre-market trading.
View original story
Similar markets
Below current level • 25%
0-25% above current level • 25%
25-50% above current level • 25%
More than 50% above current level • 25%
Above $10 • 25%
$8 to $10 • 25%
$6 to $8 • 25%
Below $6 • 25%
Above $30 • 25%
$20-$30 • 25%
$10-$20 • 25%
Below $10 • 25%
Above $25 • 25%
$20-$25 • 25%
$15-$20 • 25%
Below $15 • 25%
Decrease by more than 10% • 25%
Change between -10% and 10% • 25%
Increase by 10% to 20% • 25%
Increase by more than 20% • 25%
Below $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
Above $3 billion • 25%
Increase by more than 20% • 25%
Increase by up to 20% • 25%
Decrease by up to 20% • 25%
Decrease by more than 20% • 25%
Increase by 20% or more • 25%
Increase by less than 20% • 25%
Remain about the same • 25%
Decrease • 25%
Outperforms sector • 25%
Performs similarly to sector • 25%
Underperforms sector • 25%
No significant change • 25%
Decrease by 5% or more • 25%
Change between -5% and 5% • 25%
Increase between 5% and 10% • 25%
Increase by 10% or more • 25%
Outperform • 25%
Match • 25%
Underperform • 25%
Significantly Underperform • 25%